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Abstract
Sialyltransferases are a family of 20 gene products in mice and humans that transfer sialic acid
from its activated precursor, CMP-sialic acid, to the terminus of glycoprotein and glycolipid accep-
tors. ST3Gal-II (coded by the St3gal2 gene) transfers sialic acid preferentially to the three positions
of galactose on the Galβ1-3GalNAc terminus of gangliosides GM1 and GD1b to synthesize GD1a
and GT1b, respectively. Mice with a targeted disruption of St3gal2 unexpectedly displayed late-
onset obesity and insulin resistance. At 3 months of age, St3gal2-null mice were the same weight
as their wild type (WT) counterparts, but by 13 months on standard chow they were visibly obese,
22% heavier and with 37% greater fat/lean ratio than WT mice. St3gal2-null mice became hyper-
glycemic and displayed impaired glucose tolerance by 9 months of age. They had sharply reduced
insulin responsiveness despite equivalent pancreatic islet morphology. Analyses of insulin recep-
tor (IR) tyrosine kinase substrate IRS-1 and downstream target Akt revealed decreased insulin-
induced phosphorylation in adipose tissue but not liver or skeletal muscle of St3gal2-null mice.
Thin-layer chromatography and mass spectrometry revealed altered ganglioside proﬁles in the
adipose tissue of St3gal2-null mice compared to WT littermates. Metabolically, St3gal2-null mice
display a reduced respiratory exchange ratio compared to WT mice, indicating a preference for
lipid oxidation as an energy source. Despite their altered metabolism, St3gal2-null mice were
hyperactive. We conclude that altered ganglioside expression in adipose tissue results in dimin-
ished IR sensitivity and late-onset obesity.
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Introduction
Sialic acids are abundant terminal saccharides on glycoproteins and
glycolipids that dominate the cell surfaces of vertebrate cells and tissues
(Cohen and Varki 2010). Sialoglycans are synthesized by the action of
sialyltransferases, a family of 20 enzymes (in mice and humans) that
transfer sialic acid from the activated donor CMP-sialic acid, to the glycan
terminus of a glycolipid or glycoprotein (Audry et al. 2011). The func-
tions of sialoglycans are diverse (Schauer 2009; Bauer and Osborn 2015);
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phenotypes associated with genetic disruptions in sialyltransferase
genes in mice and humans are beginning to reveal the functions of
their sialoglycan products (Taniguchi et al. 2014).
Among sialoglycans, gangliosides—sialylated glycosphingolipids
—are found at varying densities and structural complexity in all
mammalian tissues (Iwamori et al. 1984), where they regulate cell
function and mediate intracellular recognition (Todeschini and
Hakomori 2008). Gangliosides are unusually abundant in the brain,
but function as signal transduction regulatory molecules in many tis-
sues where they are expressed in lower amounts (Allende and Proia
2014; Schnaar et al. 2014; Schnaar 2016). Among their functions,
gangliosides regulate signaling by lateral association with receptor
tyrosine kinases (Kaucic et al. 2006; Sonnino and Prinetti 2010),
including the insulin receptor (IR) (Lipina and Hundal 2015), epi-
dermal growth factor receptor (Liu et al. 2008), platelet-derived
growth factor receptor (Mitsuda et al. 2002) and the TrkA high-
afﬁnity nerve growth factor receptor (Zakharova et al. 2014).
Gangliosides are synthesized stepwise (Figure 1) by a series of gly-
cosyltransferases, some of which transfer sugars exclusively to glyco-
lipid acceptors (Schnaar et al. 2014). Two of the 20 mammalian
sialyltransferases, ST3Gal-II and ST3Gal-III, are responsible for add-
ing the terminal sialic acid to 2 abundant gangliosides in mammals,
GM1 and GD1b, to synthesize GD1a and GT1b, respectively
(Sturgill et al. 2012). Genetic deletion of the gene that codes for
ST3Gal-II (St3gal2) reduces GD1a/GT1b levels in the brain by about
half, whereas knocking out the gene that codes for ST3Gal-III
(St3gal3) has no signiﬁcant effect on ganglioside biosynthesis.
However, knocking out both St3gal2 and St3gal3 results in near total
loss of GD1a and GT1b in the brain with commensurate increases in
their precursors GM1 and GD1b. Notably, brain protein sialylation
is quantitatively unchanged in St3gal2-null mice, but is decreased
in St3gal3-null mice (Sturgill et al. 2012; Yoo et al. 2015). These data
indicate that ST3Gal-II acts primarily or exclusively on glycosphingo-
lipid acceptors. While studying St3gal2-null mice, we unexpectedly
observed that older mice lacking the ST3Gal-II enzyme appeared
obese. Since gangliosides have been reported to modulate IR signaling
(Inokuchi 2014; Lipina and Hundal 2015), we initiated studies to
document obesity and insulin resistance in St3gal2-null mice.
Results
St3gal2-null mice develop late-onset obesity
Mice lacking the enzyme ST3Gal-II (St3gal2-null mice) had a readily
apparent age-dependent increase in body mass compared to wild
type (WT) littermates when fed a regular chow diet (Figure 2A).
Young adult (3-month-old) St3gal2-null mice were the same average
weight as WT littermates (Figure 2B). However, the null mice stead-
ily gained weight >50% faster (2.2 g/month) than their WT counter-
parts (1.4 g/month), resulting in a highly signiﬁcant weight
difference by 13 months of age. Upon sacriﬁce and dissection, all
St3gal2-null mice had readily visible fat deposits in all organs (data
not shown). Thirteen-month-old St3gal2-null and WT mice were
scanned by quantitative nuclear magnetic resonance (QNMR) to
determine fat, lean and water content. The results (Table I) revealed
an increase of 50% in fat mass in St3gal2-null mice and of 9% in
lean body mass with no change in water content. When the fat mass
was normalized with lean mass, a signiﬁcant increase of 37%
(P< 0.005) in fat/lean weight ratio was observed in St3gal2-null
mice compared to WT littermates. The data support the conclusion
that St3gal2-null mice develop late-onset obesity.
St3gal2-null mice have late-onset hyperglycemia,
reduced glucose clearance and insulin resistance
To test whether obesity in St3gal2-null mice is related to changes in
insulin responsiveness, glucose clearance and insulin sensitivity were
determined. At 9 months of age, St3gal2-null mice had fasting blood
glucose levels that were 33% higher than their WT littermates
(P< 0.05; Figure 3A). Younger St3gal2-null mice (3 month old) had
a slightly higher average fasting blood glucose level than WT mice
that was not statistically signiﬁcant. Over the next 6 months, the
Fig. 2. St3gal2-null mice develop late-onset obesity. (A) Compared to their WT
counterparts, 13-month-old St3gal2-null mice are visibly obese. (B) Developmental
course of obesity in WT and St3gal2-null mice. Genotypes are signiﬁcantly differ-
ent by two-way analysis of variance (ANOVA) with P<0.001. *P<0.01 between
genotypes by post-hoc Tukey analyses. n = 6–22 mice per group.
Fig. 1. Structures and biosynthetic pathways of major mammalian ganglio-
sides. Symbols are according to Varki et al. (2015). †, in St3gal2-null mice ter-
minal α2,3 sialylation of gangliosides GM1 and GD1b to produce GD1a and
GT1b is partially compensated by the product of the St3gal3 gene, ST3Gal-III
(Sturgill et al. 2012). This ﬁgure is available in black and white in print and in
color at Glycobiology online.
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increase in fasting blood glucose was not signiﬁcantly increased in
WT mice but was signiﬁcantly increased in St3gal2-null mice.
Glucose tolerance tests revealed that 3-month-old St3gal2-null and
WT mice had similar glucose tolerance curves, with a modest but
signiﬁcant decrease in clearance only at 15min after glucose injec-
tion (Figure 3B). In contrast, 9-month-old St3gal2-null mice had sig-
niﬁcantly reduced glucose clearance compared to control over the
entire time course measured.
Since prior studies reported that gangliosides can regulate IR sen-
sitivity (Yamashita et al. 2003; Holland et al. 2007), insulin respon-
siveness was tested as a mechanism for hyperglycemia and obesity in
St3gal2-null mice (Figure 4). Fasting serum insulin levels were not
statistically different between St3gal2-null and WT mice, despite a
trend toward higher levels in the null mice (P = 0.064, Figure 4A).
However, blood glucose levels in 9-month-old St3gal2-null mice
were signiﬁcantly less responsive to intraperitoneal insulin injection
compared to WT mice (Figure 4B). The initial insulin-induced drop
in blood glucose in St3gal2-null mice is less than half that in WT mice.
More notably, blood glucose levels continued to decrease in response
to insulin in WT mice over the course of the 2-h experiment, whereas
blood glucose levels in St3gal2-null mice quickly returned to pre-
insulin levels by 60min after insulin administration. These data are
consistent with insulin resistance due to loss of ST3Gal-II.
Morphometric analyses of pancreatic sections revealed that
St3gal2-null mice and their littermate WT controls had β-islets of
the same area, aspect and general appearance (Figure 4C and data
not shown).
To conﬁrm insulin resistance at the molecular level and deter-
mine the potential tissue site(s) of insulin resistance, three major
insulin target tissues, adipose tissue, liver and skeletal muscle, were
collected from 9-month-old WT and St3gal2-null mice challenged
with insulin (1U/kg body weight) and insulin signaling studied by
analysis of the phosphorylation levels of an upstream broadly distrib-
uted IR substrate, IR substrate 1 (IRS-1) and a downstream key inter-
mediate in insulin-mediated metabolic control, the serine-threonine
kinase Akt (Guo 2014; Saltiel 2016). Levels of phosphorylated IRS-1
were decreased nearly 68% and Akt-P by 49% in adipose tissue from
St3gal2-null mice, whereas their levels were not decreased in skeletal
muscle (Figure 5, Table II). Liver had a modest, 29% decrease in
phosphorylated IRS-1 and no decrease in Akt-P. These data indicate
deﬁcits in insulin-induced molecular signaling in adipose tissue of
St3gal2-null mice.
St3gal2-null mice have altered adipose ganglioside
expression
Because adipose tissue displayed altered insulin sensitivity in
St3gal2-null mice compared to WT littermates, gangliosides were
extracted from adipose tissues and analyzed by thin-layer chroma-
tography (TLC, Figure 6) and mass spectrometry (MS) (Figures 7
and 8, Table III).
TLC analysis of WT adipose tissue revealed at least 16 resolved
ganglioside species (Figure 6A), characteristic of gangliosides with
different ceramide lipids as well as different glycans (Keranen 1976).
Based on TLC migration and quantitative analyses of sialic acid
staining, the major ganglioside of WT mouse adipose tissue was
Table I. QNMR body mass and Oxymax metabolic proﬁlesa of
13-month-old WT and St3gal2-null littermates
Metric WT St3gal2-null Null/WT P-valueb
Weight (g) 37.6 ± 0.7 45.9 ± 1.0 1.22 <0.001
Fat mass (g) 12.8 ± 0.9 19.2 ± 0.5 1.50 <0.005
Lean mass (g) 22.6 ± 0.3 24.7 ± 0.7 1.09 <0.05
%fat 34.0 ± 1.9 41.9 ± 0.7 1.23 <0.005
Fat/lean ratio 0.57 ± 0.05 0.78 ± 0.02 1.37 <0.005
VO2
c 3000 ± 106 2560 ± 34 0.85 <0.005
VCO2
c 2960 ± 96 2450 ± 44 0.96 <0.001
RER 0.99 ± 0.01 0.96 ± 0.01 0.97 <0.02
EEc 15.1 ± 0.5 12.8 ± 0.2 0.85 <0.005
VO2
d 4970 ± 93 4760 ± 97 0.97 0.15
VCO2
d 4910 ± 66 4570 ± 109 0.97 <0.05
RER 0.99 ± 0.01 0.96 ± 0.01 0.97 <0.02
EEd 25.0 ± 0.4 23.8 ± 0.5 0.95 0.10
aVO2, oxygen consumption rate (mL/kg/h); VCO2, carbon dioxide produc-
tion rate (mL/kg/h); RER, respiratory exchange ratio; EE, energy expenditure
(kcal/kg/h).
bStudent’s t-test, n = 6 per genotype.
cNormalized to kg body weight.
dNormalized to kg lean weight.
Fig. 3. St3gal2-null mice display age-related hyperglycemia and altered glucose clearance. (A) St3gal2-null mice (null) have increased blood glucose levels with
respect to WT littermates at 9 months of age. Genotypes are signiﬁcantly different by two-way ANOVA (P< 0.05). *P< 0.05, Tukey post-hoc analysis. n= 6–9
mice each group. (B) Glucose clearance was measured by peritoneal glucose solution administration (t = 0) with measurement of blood glucose for 2 h there-
after. Genotypes are signiﬁcantly different by two-way ANOVA (P< 0.02 at 3 months, P< 0.001 at 9 months). *P< 0.01; **P< 0.001 by Tukey post-hoc analyses.
Some values at 30–60min for 9-month-old null mice reached the maximum of the analytical technique (600mg/dL). Data are expressed as mean ± SE n = 7–9
mice per group.
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GM3 with signiﬁcant amounts of GM2, GM1, GD1 (GD1a and/or
GD1b) and GT1b. St3gal2-null adipose tissue had reduced GM3
expression, increased GM1 expression (conﬁrmed using TLC
immuno-overlay with anti-GM1 monoclonal antibody, data not
shown), and an absence of GT1b (Figure 6B). Although TLC stain-
ing of GD1 species was equivalent between WT and St3gal2-null
mice, distinguishing between GD1a and GD1b was not possible
using this technique due to heterogeneity of ceramide species and
overlapping migration with standards. However, TLC immuno-
overlay (using anti-GD1a monoclonal antibody) revealed a 67%
decrease in GD1a in St3gal2-null mice compared to WT (data not
shown). GD3 (which migrates near GM1) was not quantitatively
signiﬁcant by MS analyses (see below).
MS of permethylated gangliosides was consistent with the TLC
data, and revealed signiﬁcant differences in St3gal2-null mouse
adipose tissue ganglioside expression compared to that in WT
mice (Figures 7 and 8). GM3 was the major ganglioside species in
WT mice, with a remarkable 27 distinct species of GM3 identiﬁed
based on different sialic acid N-acyl groups (N-acetyl (Neu5Ac) or
N-glycolyl (Neu5Gc)) and ceramide lipid variations. WT mice expressed
more GM3 (and different GM3 species, Table III), whereas St3gal2-
null mice expressed more GM1. Masses for GD3 were not detected
Fig. 5. Reduced phosphorylation of IR effectors IRS-1 and Akt in adipose tissue from St3gal2-null mice. Nine-month-old WT (n= 3) and St3gal2-null (null, n= 3)
mice were treated with insulin (1 U/kg body weight) and then tissues were dissected, extracted and the extracted proteins were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Resolved proteins were blotted to nitrocellulose membranes and immunoblotted with antibodies to
phospho-IRS-1 (P-IRS-1), IRS-1 (IRS), phospho-Akt (P-Akt) and Akt. Images were scanned and quantitative results are reported in Table II.
Table II. Phosphorylation of IR effector proteins IRS-1 and Akta in different tissues of 9-month-old WT and St3gal2-null mice
Adipose Liver Skeletal muscle
Genotype IRS-P/IRS Akt-P/Akt IRS-P/IRS Akt-P/Akt IRS-P/IRS Akt-P/Akt
WT 2.3 ± 0.9 1.8 ± 0.5 1.0 ± 0.1 0.9 ± 0.1 1.1 ± 0.2 1.4 ± 0.1
St3gal2-null 0.7 ± 0.3 0.9 ± 0.1 0.7 ± 0.2 1.2 ± 0.1 1.2 ± 0.1 1.5 ± 0.1
Null/WT ratio 0.32 0.51 0.71 1.2 1.1 1.0
aPixel intensities of bands on images of immunoblots were analyzed using ImageJ and total density per band determined. Values for phosphoproteins (arbitrary
units) were divided by values for total proteins of each type and are reported as ratios.
Fig. 4. St3gal2-null mice display marked insulin resistance. (A) Serum insulin levels are not signiﬁcantly different between St3gal2-null (null) and WT mice. P =
0.064, n= 15–17 mice per group. (B) Insulin responses of WT and St3gal2-null mice. Insulin was injected intraperitoneally at t= 0 and blood glucose levels mea-
sured at indicated times up to 2 h thereafter. Values are expressed as percent difference from the value at t= 0. Genotypes are signiﬁcantly different by two-way
ANOVA (P< 0.001). *P< 0.005 by Tukey post-hoc analyses. n= 5–7 mice per group. (C) Morphometric analyses of β-islet size shows no signiﬁcant difference
between WT and St3gal2-null (null) mice (P= 0.28 by Student’s t-test). n= 3 mice per group. Data are from pancreas cross sections (images not shown).
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in either sample, and higher order gangliosides were either very
minor (GD1) or absent (GT1b) in the MS-processed samples.
Quantitative analyses (Figure 8, Table III) revealed that, as in the
TLC analyses, St3gal2-null mouse adipose tissue had relatively less
GM3 and more GM1 expression. The GM3 Neu5Ac:Neu5Gc ratio
was the same between null and WT mice, whereas the amount of
hydroxy fatty acid in GM3 ceramide was relatively higher in St3gal2-
null mice (Figure 8). Ceramide heterogeneity was much less in GM1
species, with only three fatty acids (C16:0, C24:1 and C24:0) pre-
dominating (data not shown). Total GM1 levels were >10-fold
higher in St3gal2-null mice, with an increase in the Neu5Ac:
Neu5Gc ratio and no difference in relative fatty acid hydroxylation
(Figure 8).
Total glycoprotein sialic acid was quantitatively unchanged in
St3gal2-null mouse adipose tissue (104% ± 11% compared to WT
mice, n= 3 of each genotype).
Insulin-induced phosphorylation of Akt in mouse
3T3-L1 adipocytes is increased by preincubation with
exogenous GM3 or GT1b, but not GM1
Ganglioside analyses (Figure 6) indicate increased GM1 with
decreased GT1b and GM3 in St3gal2-null adipose compared to WT
mouse adipose. To test whether these gangliosides alter insulin sig-
naling when added exogenously, each was added to mouse 3T3-L1
adipocytes for 24 h prior to testing cellular insulin responses.
Whereas exogenous GM1 had no effect on insulin-induced Akt
phosphorylation (Figure 9), surprisingly both GT1b and GM3 sig-
niﬁcantly increased insulin signaling.
St3gal2-null mice have reduced energy metabolism
and increased locomotor activity
Indirect calorimetry was used to characterize metabolic changes con-
tributing to obesity in St3gal2-null mice (Table I). Compared to WT
littermates, St3gal2-null mice displayed a reduction in rates of oxy-
gen consumption normalized to body weight. Similar percent
decreases were found during light and dark periods (comparison
data not shown). The respiratory exchange ratio (RER) was also sig-
niﬁcantly decreased in St3gal2-null mice compared to WT mice, sug-
gesting an increase in β-oxidation of lipids as their source of energy.
There was no signiﬁcant difference in the RER during the light (rest)
cycle (0.96, WT and null mice), but St3gal2-null mice showed a
marked reduction in RER during the dark (active) cycle (1.01 for
WT; 0.95 for null mice, P< 0.0005). Compared to WT littermates,
St3gal2-null mice also displayed a reduction in energy expenditure
Fig. 7. Total ion mapping MS of gangliosides extracted from WT and St3gal2-
null mouse adipose tissues as described in the text and legend to Figure 6.
Signal intensities are expressed as a percent of total ganglioside-related signals.
Fig. 6. Altered ganglioside expression in adipose tissue from St3gal2-null mice. (A) Gangliosides from visceral adipose tissue from adult WT and St3gal2-null
(null) mice (11 months old) were extracted, partially puriﬁed, subjected to silica gel TLC and stained with the sialic acid-speciﬁc resorcinol reagent. Samples
were loaded at equivalent weights of adipose tissue. Ganglioside standards are identiﬁed at the left and adipose ganglioside assignments (based on migration
and immuno-overlay) to the right. The image was uniformly contrast enhanced for presentation. (B) Images of stained TLC plates (not contrast enhanced) were
subjected to quantitative image analysis using ImageJ software. Relative staining densities were adjusted for the number of sialic acids in each species and are
expressed as percent of total gangliosides. This ﬁgure is available in black and white in print and in color at Glycobiology online.
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(EE) normalized to body weight. St3gal2-null mice did not have
increased food intake (g/d, 5.3 ± 0.2 for WT; 5.4 ± 0.1 for nulls),
ruling out hyperphagia as a signiﬁcant contributing factor to the
obesity. It is notable that while RER differences were signiﬁcant
when data were normalized to body weight or lean weight, the
reduction in oxygen consumption in St3gal2-null mice was only sig-
niﬁcant when normalized to body weight (Table I), results consistent
with selectively altered adipose metabolism.
To test whether reduced locomotor activity contributed to obesity
in St3gal2-null mice, open-ﬁeld activity was measured over a 24-h
period using automated photometric cages. Far from being lethargic,
the St3gal2-null mice had increased locomotor activity during the
active (dark) cycle (Figure 10). These results are consistent with
increased locomotor activity reported in B4galnt1-null mice (Pan
et al. 2005), which have a block in ganglioside metabolism upstream
of ST3Gal-II activity (see Figure 1). Considered together, metabolic
Table III. GM3 structures in adult WT and St3gal2-null mouse (11 months old) adipose tissuesa
Fatty acid WT St3gal2-null
Neu5Ac Neu5Gc Neu5Ac Neu5Gc
NH-FA (%) OH-FA (%) NH-FA (%)b NH-FA (%) OH-FA (%) NH-FA (%)b
C16:0 4.8 3.2 3.0 2.9 13.8 6.0
C18:0 5.3 1.7 0.8 0.8 4.8 1.5
C20:0 3.6 2.2 0.3 0.8 5.1 1.2
C22:0 8.8 8.1 2.5 1.1 8.6 1.7
C23:1 0.9 0.6 2.9 1.0
C23:0 5.1 4.9 2.1 4.5 1.2
C24:1 5.9 3.5 5.2 3.7 14.1 4.7
C24:0 7.7 6.0 5.9 2.3 7.7 3.3
C24:0 phyt 0.5 0.3
C24:1 phyt 1.0 1.1
C26:1
C27:0 0.3
C26:0 phyt 0.8 1.0 2.7
C27:0 phyt 1.9
C28:0 phyt 3.4
TOTALS 41.9 36.8 20.5 14.4 63.3 22.0
aFatty acid assignments (NH-FA, nonhydroxy fatty acids; OH-FA, hydroxy fatty acids) are based on mass assuming d18:1 sphingosine. MS2 data were used to
determine Neu5Ac:Neu5Gc ratios for masses indicating a single extra hydroxy group, which was assigned to Neu5Gc or the fatty acid. phyt = species with masses
consistent with phytosphingosine as the ceramide base.
bLess than 1% of GM3 species (0.8% WT, 0.3% St3gal2-null) was found as Neu5Gc-GM3 with hydroxy fatty acids (data not shown).
Fig. 8. Comparative ganglioside expression in WT and St3gal2-null mice. The summed MS signal (see Fig. 7) for each ganglioside species detected (left panel)
are expressed a percent of total ganglioside signals. Within the species of GM3 (Table III) and GM1 detected, the percent expression of Neu5Ac vs. Neu5Gc as
well as percent of total gangliosides with hydroxy fatty acids are shown (right panel).
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and open-ﬁeld activity data are consistent with altered metabolic
regulation rather than altered mobility contributing to obesity in
St3gal2-null mice.
Discussion
Mice lacking the enzyme ST3Gal-II exhibit insulin resistance and
obesity. ST3Gal-II is highly selective for adding α2,3-sialic acid to
the terminal galactose of the acceptor disaccharide Galβ1-3 GalNAc,
with very low activity for Galβ1-3GlcNAc and none for Galβ1-
4GlcNAc (Tsuji and Takashima 2014). The preferred Galβ1-
3GalNAc acceptor determinant is abundant as the terminus on the
major gangliosides GM1 and GD1b, which are converted by
ST3Gal-II to GD1a and GT1b, respectively (Sturgill et al. 2012).
Although the same acceptor disaccharide is found on O-linked gly-
coproteins (the T-antigen), kinetic studies indicate that gangliosides
are the predominant acceptors for ST3Gal-II, whereas O-linked gly-
coproteins are better acceptors for ST3Gal-I (Tsuji and Takashima
2014). Furthermore, data from brain (Sturgill et al. 2012; Yoo et al.
2015) and adipose (this article) indicate that total glycoprotein sialy-
lation is quantitatively unchanged in tissues of St3gal2-null mice.
Although it is possible that some O-linked glycoprotein glycans are
altered in these St3gal2-null mice, the simplest hypothesis consistent
with these data is that changes in adipose ganglioside (glycosphingo-
lipid) sialylation are responsible for an insulin-resistant phenotype.
Multiple lines of evidence indicate that the simple ganglioside
GM3 (see Figure 1) regulates IR sensitivity via direct lateral interac-
tions with the IR in the plane of the membrane (Inokuchi 2014;
Lipina and Hundal 2015). Those data support a model in which
GM3-IR interactions sequester the IR from caveolae, inhibiting
IR-mediated signaling (Kabayama et al. 2007). Increasing GM3 synthe-
sis by treatment with TNF-α suppresses IR signaling, with the TNF-α
effect pharmacologically reversed by blocking GM3 biosynthesis
(Tagami et al. 2002). In vivo, evidence supporting GM3 as a regula-
tor of insulin sensitivity comes from mice genetically engineered to
lack GM3 (Yamashita et al. 2003). Although GM3-deﬁcient mice
(St3gal5-null) were viable and without major abnormalities, they
displayed enhanced IR phosphorylation and were protected from
high-fat diet-induced insulin resistance (Yamashita et al. 2003;
Nagafuku et al. 2015). Consistent with these ﬁndings, pharmaco-
logical inhibition of glycosphingolipid biosynthesis at the level of
glucosylceramide enhances insulin sensitivity in vitro (Kabayama
et al. 2007) and in vivo (Aerts et al. 2007; Zhao et al. 2007; van
Eijk et al. 2009; Yew et al. 2010). Together, these data support the
conclusion that ganglioside GM3, in particular, down-regulates IR
sensitivity.
Exogenous addition of gangliosides to intact cultured cells has
the potential to result in membrane insertion. Prior studies adding
gangliosides to mouse 3T3 adipocytes in culture revealed that GM3
(100 μM) but not GD1a reduced insulin-mediated IR self-
phosphorylation and to a lesser extent IRS-1 phosphorylation
(Tagami et al. 2002). In this study, using 50 μM exogenous ganglio-
side complexed with fatty acid-free BSA, GM1 had no effect,
whereas GM3 (and GT1b) increased IRS-1 and Akt phosphoryl-
ation. The difference in the outcome of GM3 exogenous addition in
this study may relate to the source of GM3, which was from bovine
milk in the prior study and from canine blood in this study.
Differences in ceramide structures, notably in fatty acid chain lengths,
may account for different biological effects (or pharmacological effects
of endogenously added gangliosides). The highly varied GM3 cera-
mide structures found in mouse adipose tissues in this study invite the
hypothesis that diverse GM3 lipid structures may drive diverse molecu-
lar interactions. Prior studies on ganglioside-mediated regulation of
Fig. 10. St3gal2-null mice display increased locomotor activity. Open-ﬁeld
activity of 6-month-old WT and St3gal2-null (null) mice was automatically
quantiﬁed over a 24-h period using photometric beams. The ﬁrst 12 h repre-
sents the dark cycle and the last 12 h the light cycle. Null mice were signiﬁ-
cantly more active than WT (P< 0.005, two-way ANOVA). *P< 0.05, Tukey
post-hoc analyses. Data are expressed as mean ± SE n= 6 mice per group.
Fig. 9. Exogenous addition of gangliosides GM3 and GT1b (but not GM1)
to 3T3-L1 adipocytes enhances insulin-mediated Akt phosphorylation.
Adipocyte-differentiated 3T3-L1 cells were cultured for 24 h in medium con-
taining 50 μM BSA (control) or 50 μM ganglioside–BSA complex as indicated.
After washing, cells were treated for 5min with 10 nM insulin, lysed, and the
relative amount of phosphorylated Akt compared to total Akt was deter-
mined by immunoblotting. Data are expressed as the ratio of arbitrary dens-
ity units. Cells treated with GM3 or GT1b (but not GM1) had a higher relative
phospho-Akt than WT (P< 0.001, two-way ANOVA). *P< 0.001, Tukey post-
hoc analyses. Data are expressed as mean ± SE n= 3 replicate cultures per
group. BSA, bovine serum albumin.
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tyrosine kinase receptors have addressed differential effects of the
same ganglioside on the same receptor system depending on cell
type, ganglioside species (both carbohydrate and lipid) and experi-
mental conditions (Kaucic et al. 2006).
The published evidence of gangliosides other than GM3 in regu-
lating insulin sensitivity is less clear. Insulin-induced autophosphory-
lation of solubilized and partially puriﬁed IR’s from lymphoblast
cells or skeletal muscle is reduced by addition of several gangliosides
to the receptor phosphorylation assays, including GM3, GM2, GM1,
GD1a and GT1b (Nojiri et al. 1991; Sasaki et al. 2003). Recently,
increased ganglioside GM1 was associated with reduced insulin sen-
sitivity in late-passage (senescent) human endothelial cells in culture
(Sasaki et al. 2015). However, genetic evidence for the roles of gang-
liosides other than GM3 in regulating the IR has been limited. Data
from this study are consistent with the hypothesis that a shift from
higher gangliosides (GD1a, GT1b) to GM1 in adipose tissue contri-
butes to insulin resistance, and that St3gal2-null mice are a genetic
model of late-onset diabetes. Changes in GM3 molecular species,
which were also found, may be an outcome or a contributing factor
to obesity. The notable shift toward hydroxy fatty acids in the cera-
mide of GM3 from St3gal2-null mice is notable in light of recent data
demonstrating differential enhancement of GM3 fatty acid hydroxyl-
ation in humans with metabolic syndrome (Veillon et al. 2015). The
question of whether these changes are an outcome or cause of obesity
in both mice and humans is worthy of further investigation. Genetic
alteration of fatty acid chain length in sphingolipids (including but not
exclusively gangliosides) is associated with insulin resistance in liver
but not adipose, indicating yet another level of sphingolipid control of
insulin sensitivity (Park et al. 2013).
Loss of ST3Gal-II resulted in impaired whole-body insulin sensi-
tivity, as indicated by a reduced glucose shift into peripheral tissues
in response to either glucose or insulin challenges. This study
demonstrates insulin resistance, as measured by decreased insulin-
mediated substrate and downstream target phosphorylation, primarily
in adipose tissue. Consistent with this ﬁnding, mouse adipose tis-
sue expresses complex gangliosides including GM1, GD1a, GD1b
and GT1b (Figure 6 and Ohashi 1979). A reasonable hypothesis
consistent with these data is that increased GM1 and/or decreased
GD1a and GT1b is/are responsible for impaired insulin action in
St3gal2-null mice. In this light, the ability to exogenous GT1b but
not GM1 to enhance insulin-mediated insulin signaling (Figure 9)
may be relevant. Compared to mouse adipose, mouse liver and mus-
cle have little or no GM1 or higher gangliosides (Sasaki et al. 2003),
consistent with the relative lack of altered insulin-stimulated signal-
ing in these tissues in St3gal2-null mice. By comparison, transgenic
mice overexpressing the ganglioside sialidase gene NEU3 in all tis-
sues developed a diabetic phenotype, whereas selective overexpres-
sion of NEU3 in liver had the opposite effect (Sasaki et al. 2003;
Lipina et al. 2015). These data may be explained by considering the
substrates of Neu3 sialidase. GM3 is eliminated by Neu3, whereas
gangliosides GD1a, GD1b and GT1b are converted to GM1 (GM1
and GM2 are resistant to this sialidase) which may induce insulin
resistance. In tissues expressing primarily GM3, Neu3 may increase
insulin sensitivity, whereas in tissues with GD1a and GT1b, conver-
sion to GM1 may result in insulin resistance. Therefore, the effects
of Neu3 sialidase would be tissue-speciﬁc.
The obese phenotype in St3gal2-null mice was late-onset, with
mice showing a signiﬁcant increase in body weight at 5 months.
Nevertheless, St3gal2-null mice displayed mildly but signiﬁcantly
reduced clearance of blood glucose at 3 months of age, before a sig-
niﬁcant increase in body weight was apparent, suggesting that
insulin resistance preceded obesity. Poor glucose clearance in these
mice was attributed, at least in part, to reduced IR sensitivity as
judged by their impaired signaling in response to exogenous insulin.
Our conclusion is that a shift in complex ganglioside levels in adi-
pose (increased GM1, decreased GD1a and GT1b) results in insulin
resistance, and that St3gal2-null mice display a late-onset obese dia-
betic phenotype. Although the causative role (if any) of ganglioside
shifts in the etiology of diabetes is unknown, it may be relevant that
adipose tissue from diet-induced obese insulin-resistant mice have
increased complex gangliosides including GM2, GM1 and GD1a
(Tanabe et al. 2009). Given these observations, the relationships
between obesity, diabetes and ganglioside expression patterns in adi-
pose tissue are worth further consideration.
Materials and methods
Mice
St3gal2-null mice were produced by targeted gene disruption as
described previously (Ellies et al. 2002). Genotypes were deter-
mined using polymerase chain reaction (PCR) with oligonucleotide
primers 5′-CTTTGCGACAGGGTTTCATT and 5′-CAGGGTT
GCTCAACAAGTG. Alternatively, genotyping was outsourced for
determination by real time PCR (Transnetyx, Cordova, TN). Mice
were routinely maintained in a 14-h light/10-h dark cycle and fed
with standard mouse chow (Harlan Teklad 2018SX, Harlan
Laboratories, Indianapolis, IN). All procedures were approved by
Institutional Animal Care and Use Committees and were consistent
with federal law and National Institutes of Health (NIH) regulations.
Ganglioside and sialoglycoprotein analyses
Gangliosides were extracted and quantiﬁed as previously reported
(Schnaar 1994). Brieﬂy, 0.4–1.3 g of visceral adipose was homoge-
nized on ice in 10 volumes of water (W) using a Potter-Elvehjem
homogenizer. At ambient temperature, methanol (M) and then
chloroform (C) were added to give a ratio of C–M–W (4:8:3). After
thorough mixing, insoluble material was removed by centrifugation
(1250 × g, 15min), the supernatant collected and the pellet saved
for sialoglycoprotein determination. The supernatant was loaded
onto a 3-mL column of DEAE-Sepharose (acetate form), the column
washed with C–M–W (4:8:3) and methanol, and gangliosides eluted
with 200mM ammonium acetate in methanol. The eluate was eva-
porated under a stream of nitrogen and treated with 2mL of 0.5M
NaOH in methanol at 60°C for 2 h. Samples were cooled, neutralized
with 0.5M acetic acid, adjusted by solvent addition to C–M–W
(2:43:55) and loaded onto a tC18 Sep-Pak cartridge (Waters, Milford,
MA). The cartridge was washed with the same solvent mixture,
methanol–water (1:1) and then gangliosides eluted with methanol.
The eluate was evaporated under vacuum and redissolved in methanol
at 50 μL per gram of original tissue for analyses.
Aliquots were subjected to silica gel TLC using chloroform–
methanol−0.25% aqueous KCl (60:35:8) as developing solvent.
Gangliosides were visualized using a quantitative sialic acid-speciﬁc
colorimetric resorcinol reagent (Schnaar and Needham 1994). The
plates were scanned and resorcinol-stained spots quantiﬁed using
ImageJ (Research Services Branch, National Institute of Mental
Health). Alternatively, gangliosides GM1 and GD1a were detected
after TLC resolution by immuno-overlay using anti-ganglioside anti-
bodies as described (Lopez and Schnaar 2006).
For MS analysis, dried ganglioside samples were further
puriﬁed by washing with n-hexane. The puriﬁed gangliosides were
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permethylated as described (Anumula and Taylor 1992). The per-
methylated gangliosides were further puriﬁed by dissolving in 50%
methanol and loading onto a water-prewashed tC18 Sep-Pak cart-
ridge and permethylated gangliosides eluted with pure methanol.
Maltotri- and tetra-saccharides were permethylated with 13C-methyl
iodine as internal standards.
Permethylated gangliosides were reconstituted in 50 μL of methanol/
2-propanol/1-propanol/water (16:3:3:2 by volume) containing 1mM
NaOH for infusion. Ten picomole of maltooligosaccharide standards
were spiked into each glycosphingolipid sample and the mixture was
analyzed by infusion into a linear ion trap mass spectrometer (LTQ;
ThermoFisher Scientiﬁc, Waltham, MA) using a nanoelectrospray
source at a syringe ﬂow rate of 0.40–0.60 µL/min and capillary tem-
perature set to 210°C (Anumula and Taylor 1992; Vukelic et al.
2005; Aoki et al. 2007; Nimrichter et al. 2008). The instrument was
tuned with a mixture of permethylated glycosphingolipid standards
for positive ion mode. For fragmentation by collision-induced dis-
sociation (CID) in MS/MS and MSn, a normalized collision energy of
35–40% was used.
Detection and absolute quantiﬁcation of the prevalence of indi-
vidual gangliosides was accomplished using the total ion mapping
and neutral loss scan functionality of the Xcalibur software package
version 2.0 (ThermoFisher Scientiﬁc) as previously described (Aoki
et al. 2007). Brieﬂy, for total ion mapping, the m/z range from 600
to 2000 was automatically scanned in successive 2.8 mass unit win-
dows with a window-to-window overlap of 0.8 mass units, which
allowed the naturally occurring isotopes of each glycolipid species to
be summed into a single response, thereby increasing detection sensi-
tivity. Gangliosides were identiﬁed as singly (monosialo) or doubly
charged (disialo), sodiated species in positive mode. For neutral loss
scans, an MS workﬂow was deﬁned in which the highest intensity
peak detected by full MS was subjected to CID fragmentation.
Preliminary analysis demonstrated that the major fragment ions in
CID MS/MS scans of glycosphingolipid preparations correspond to
the neutral loss of the ceramide moiety, leaving intact glycosphingo-
lipid oligosaccharide ions. Therefore, the neutral loss scan workﬂow
was set to acquire MSn fragmentation if an MS/MS proﬁle con-
tained an ion with m/z equivalent to loss of the most prevalent cera-
mide moiety. Following this data-dependent acquisition, the
workﬂow returned to the full MS, excluded the parent ion just frag-
mented and chose the peak of next highest intensity for the same
MS/MS and MSn analysis. By this data-dependent acquisition work-
ﬂow, glycosphingolipid glycan proﬁles and MSn sequencing were
rapidly acquired for complex mixtures.
Fatty acid assignments were based on mass assuming d18:1
sphingosine. MS2 data were used to determine Neu5Ac:Neu5Gc
ratios for every ganglioside mass. For every mass containing an
extra permethylated hydroxy group, each was assigned to either
Neu5Gc or the fatty acid depending on the predetermined Neu5Ac:
Neu5Gc ratio. Signal assignments for overlapping monoisotopic
peaks (e.g. the same ganglioside with C24:1 and C24:0 fatty acids)
were arbitrarily assigned to the higher mass partner.
For glycoprotein sialic acid determinations, the methanol–
chloroform–water precipitate containing the cellular proteins (see
above) was dried at ambient temperature, then was fully solubilized
in 0.1M aqueous NaOH. Aliquots of solubilized brain protein were
neutralized with HCl, then dissolved in 0.1M HCl, 0.25M NaCl
and heated at 80°C for 3 h. Aliquots of the acid hydrolysates were
analyzed for sialic acid using Dionex strong anion exchange high-
performance liquid chromatography coupled with pulsed ampero-
metric detection as described previously (Rohrer 2000). Aliquots of
standard sialic acid of known concentration were hydrolyzed in par-
allel to correct for recovery.
Glucose tolerance, insulin responsiveness and insulin
levels
Glucose tolerance was determined in St3gal2-null mice and age-
matched WT littermate controls (n= 8 each group). Mice were
fasted for 15 h prior to testing. On the day of the test, mice were
weighed and their fasting blood glucose level was measured on
freshly collected tail vein blood using an ACCU-CHEK Aviva blood
glucose meter (Roche Diagnostics, Indianapolis, IN) with a detection
range of 20–600mg/dL (detection based on glucose oxidase reac-
tion). Mice were then injected intraperitoneally with 2 g/kg body
weight of D-glucose as a 20% saline solution and tail vein blood glu-
cose levels were determined 15, 30, 60 and 120min thereafter.
Insulin responsiveness was determined after measurement of fasting
blood glucose (as above). Mice were injected intraperitoneally with
0.75U/kg body weight of diluted Regular Human Insulin (HumulinR,
Eli Lilly and Company, Indianapolis, IN) and blood glucose levels were
determined (as above) 15, 30, 60 and 120min thereafter.
Serum insulin levels were determined using tail vein blood of
9-month-old mice (n= 10 per group) that had been fasted for 15 h.
Sera were separated and stored at −70°C prior to testing. Serum
insulin levels were determined with an Ultrasensitive Mouse Insulin
ELISA kit (Mercodia AB, Uppsala, Sweden) according to the manu-
facturer’s instructions.
Phosphorylation of IR effectors
For insulin signaling analyses, 9-month-old St3gal2-null and WT lit-
termates were fasted for 15 h before being given an intraperitoneal
injection of insulin (1 U/kg body weight). Adipose, liver and soleus
muscle were then dissected and homogenized immediately in ice-cold
Tissue Protein Extraction Reagent (ThermoFisher) supplemented
with protease inhibitors (Roche Applied Science, Indianapolis, IN)
and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). The pro-
tein content of the supernatant was determined using the Pierce BCA
protein assay kit (ThermoFisher). Equal protein amounts of each
sample were boiled for 4min at 100°C after the addition of an equal
amount of 2× SDS loading buffer. The proteins were separated by
electrophoresis (NuPAGE 10% or 4–12% BisTris gel, Invitrogen)
according to the manufacturer’s instructions. The gels were blotted
onto nitrocellulose membranes (Bio-Rad, Hercules, CA) and
stained with Ponceau S red (Sigma-Aldrich) to conﬁrm equal load-
ing and transferring of proteins to the membrane in each lane.
Immunoblotting was performed using antibodies that recognize
phospho-Akt (Thr-308), Akt (loading control) and IRS-1 (loading
control) from Cell Signaling (Danvers, MA) and phospho-IRS-1 (Tyr-
612) from BIOSOURCE International (Camarillo, CA). Secondary
antibodies were conjugated to horseradish peroxidase, and the signals
were developed by chemiluminescence (GE Healthcare, Pittsburgh,
PA). The signals were imaged using FluorChem Q multiImage III
(AlphaInnotech, San Leandro, CA) and quantiﬁed as phospho-Akt/
Akt and phospho-IRS-1/IRS-1 ratios using ImageJ software.
Insulin-stimulated Akt phosphorylation in ganglioside-
treated 3T3-L1 adipocytes
Mouse 3T3-L1 cells were cultured in maintenance medium composed
of Dulbecco’s Modiﬁed Eagle Medium (DMEM, Invitrogen) supple-
mented with 10% fetal bovine serum and penicillin/streptomycin
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(ThermoFisher). Two days after cells reached conﬂuency, adipocyte
differentiation was induced with DMEM supplemented with 0.5mM
methylisobutylxanthine (IBMX), 1 µM dexamethasone and 4 µg/mL
insulin for 3 d and 4 µg/mL insulin for an additional 2 d. Cells were
then returned to maintenance medium for 3 d by which time >90% of
the cells differentiated into mature adipocytes laden with lipid droplets.
Gangliosides (750 nmol each of canine blood GM3 from Sigma-
Aldrich and bovine brain GM1 and GT1b from Matreya, State
College, PA) were dissolved in 1mL of DMEM containing 750 nmol
(49.5mg) of fatty acid-free BSA (Sigma-Aldrich). After gangliosides
were dissolved, each solution was diluted to 15mL (50 µM ganglio-
side–BSA) with serum-free DMEM. Adipocytes were treated with
vehicle control (50 μM BSA) or 50 μM ganglioside–BSA mixtures in
DMEM for 24 h. After washing with PBS, cells were treated with
(or without) 10 nM insulin for 5min, lysed using 20mM Tris-HCl,
150mM NaCl, 1mM EDTA, 0.5% NP-40 and 10% glycerol, and
lysates subjected to immunoblot analyses (as described under
“Phosphorylation of IR effectors”) using anti-Phospho-Akt (Ser473)
and anti-Akt (loading control) antibodies (Cell Signaling). Band
intensities on immunoblots were quantiﬁed using ImageJ software.
Body composition and calorimetry
Total body fat, lean mass and total body water were determined in
St3gal2-null mice and WT littermate controls (n= 6 per group) by
QNMR using an Echo-MRI-100TM Analyzer system (Echo Medical
Systems, Houston, TX). These studies were performed at the Johns
Hopkins University Phenotyping Core.
Indirect calorimetry was conducted using an open-ﬂow indirect
calorimeter (Oxymax Equal Flow System; Columbus Instruments,
Columbus, OH) at The Johns Hopkins Center for Metabolism and
Obesity Research. Mice were acclimated to the test facility for 1 week,
monitored during acclimation to calorimetry chambers for 3 d and
then monitored for a fourth day. Daily body weights and chow intakes
(corrected for spillage) were measured to conﬁrm acclimation. Rates of
oxygen consumption (VO2, mL/kg/h) and carbon dioxide production
(VCO2, mL/kg/h) were recorded for each chamber every 17min. RER
(VCO2/VO2) and rates of EE were calculated by Oxymax software (v.
4.02). EE was calculated using the formula EE = CV × VO2, in which
CV is the caloric value, derived from the RER and constants from the
table of Lusk (1928) (CV = 3.815 + (1.232 × RER)). Average values
for VO2, RER and EE were calculated per subject for 24 h, and for the
corresponding 12-h dark and 12-h light periods. Data were analyzed
by unpaired, two-tailed Student’s t-test.
Morphometric analyses
St3gal2-null mice and WT littermates (n= 3 each group) were trans-
cardially perfused with saline then 4% paraformaldehyde in saline.
The pancreas was harvested and further ﬁxed in 4% paraformalde-
hyde for 24 h. Five semi-serial 10-μm plastic embedded sections
from each pancreas were stained with hematoxylin-eosin to visualize
pancreatic β-islets. Images comprising the entire length of the pan-
creas were acquired using a Nikon TE300 microscope ﬁtted with a
Photometrics CoolSNAP HQ2 camera (Roper Scientiﬁc, Duluth,
GA). Morphometric studies were performed using NIS Elements
software (Nikon). Data were analyzed by Student’s t-test.
Locomotor activity
St3gal2-null and WT littermates (n= 6 each group) were placed in
photobeam activity open-ﬁeld chambers (San Diego Instruments,
San Diego, CA). Two levels of photobeams measured locomotor
and rearing activities in a test arena that was 15″ (width) × 15″
(depth) × 12″ (height).
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ANOVA, analysis of variance; EE, energy expenditure; IR, insulin receptor;
IRS, insulin receptor substrate; NIH, National Institutes of Health; QNMR,
quantitative nuclear magnetic resonance; RER, respiratory exchange ratio;
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TLC,
thin-layer chromatography; VO2, oxygen consumption; VCO2, carbon diox-
ide production. Ganglioside nomenclature is that of Svennerholm (1994).
References
Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis
PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, et al. 2007.
Pharmacological inhibition of glucosylceramide synthase enhances insulin
sensitivity. Diabetes. 56:1341–1349.
Allende ML, Proia RL. 2014. Simplifying complexity: genetically resculpting
glycosphingolipid synthesis pathways in mice to reveal function.
Glycoconj J. 31:613–622.
Anumula KR, Taylor PB. 1992. A comprehensive procedure for preparation
of partially methylated alditol acetates from glycoprotein carbohydrates.
Anal Biochem. 203:101–108.
Aoki K, Perlman M, Lim JM, Cantu R, Wells L, Tiemeyer M. 2007. Dynamic
developmental elaboration of N-linked glycan complexity in the
Drosophila melanogaster embryo. J Biol Chem. 282:9127–9142.
Audry M, Jeanneau C, Imberty A, Harduin-Lepers A, Delannoy P, Breton C.
2011. Current trends in the structure-activity relationships of sialyltrans-
ferases. Glycobiology. 21:716–726.
Bauer J, Osborn HM. 2015. Sialic acids in biological and therapeutic pro-
cesses: opportunities and challenges. Future Med Chem. 7:2285–2299.
Cohen M, Varki A. 2010. The sialome—far more than the sum of its parts.
OMICS. 14:455–464.
Ellies LG, Sperandio M, Underhill GH, Yousif J, Smith M, Priatel JJ, Kansas
GS, Ley K, Marth JD. 2002. Sialyltransferase speciﬁcity in selectin ligand
formation. Blood. 100:3618–3625.
Guo S. 2014. Insulin signaling, resistance, and the metabolic syndrome:
insights from mouse models into disease mechanisms. J Endocrinol. 220:
T1–T23.
Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA.
2007. Lipid mediators of insulin resistance. Nutr Rev. 65:S39–S46.
Inokuchi J. 2014. GM3 and diabetes. Glycoconj J. 31:193–197.
Iwamori M, Shimomura J, Tsuyuhara S, Nagai Y. 1984. Gangliosides of vari-
ous rat tissues: distribution of ganglio-N- tetraose-containing gangliosides
and tissue-characteristic composition of gangliosides. J Biochem (Tokyo).
95:761–770.
Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, Sonnino S, Kinjo M,
Igarashi Y, Inokuchi J. 2007. Dissociation of the insulin receptor and
caveolin-1 complex by ganglioside GM3 in the state of insulin resistance.
Proc Natl Acad Sci. U S A. 104:13678–13683.
Kaucic K, Liu Y, Ladisch S. 2006. Modulation of growth factor signaling by
gangliosides: positive or negative? Methods Enzymol. 417:168–185.
Keranen A. 1976. Fatty acids and long-chain bases of gangliosides of human
gastrointestinal mucosa. Chem Phys Lipids. 17:14–21.
138 PHH Lopez et al.
Lipina C, Hundal HS. 2015. Ganglioside GM3 as a gatekeeper of obesity-
associated insulin resistance: Evidence and mechanisms. FEBS Lett. 589:
3221–3227.
Lipina C, Nardi F, Grace H, Hundal HS. 2015. NEU3 sialidase as a marker of
insulin sensitivity: Regulation by fatty acids. Cell Signal. 27:1742–1750.
Liu Y, Su Y, Wiznitzer M, Epifano O, Ladisch S. 2008. Ganglioside depletion
and EGF responses of human GM3 synthase-deﬁcient ﬁbroblasts.
Glycobiology. 18:593–601.
Lopez PH, Schnaar RL. 2006. Determination of glycolipid-protein interaction
speciﬁcity. Methods Enzymol. 417:205–220.
Lusk G. 1928. Elements of the Science of Nutrition, 4th ed. Philadelphia and
London, W.B. Saunders Co. p. 844.
Mitsuda T, Furukawa K, Fukumoto S, Miyazaki H, Urano T, Furukawa K.
2002. Overexpression of ganglioside GM1 results in the dispersion of
platelet-derived growth factor receptor from glycolipid-enriched microdo-
mains and in the suppression of cell growth signals. J Biol Chem. 277:
11239–11246.
Nagafuku M, Sato T, Sato S, Shimizu K, Taira T, Inokuchi J. 2015. Control
of homeostatic and pathogenic balance in adipose tissue by ganglioside
GM3. Glycobiology. 25:303–318.
Nimrichter L, Burdick MM, Aoki K, Laroy W, Fierro MA, Hudson SA, Von
Seggern CE, Cotter RJ, Bochner BS, Tiemeyer M, et al. 2008. E-selectin
receptors on human leukocytes. Blood. 112:3744–3752.
Nojiri H, Stroud M, Hakomori S. 1991. A speciﬁc type of ganglioside as a
modulator of insulin- dependent cell growth and insulin receptor tyrosine
kinase activity. Possible association of ganglioside-induced inhibition of
insulin receptor function and monocytic differentiation induction in HL-
60 cells. J Biol Chem. 266:4531–4537.
Ohashi M. 1979. A comparison of the ganglioside distributions of fat tissues
in various animals by two-dimensional thin layer chromatography.
Lipids. 14:52–57.
Pan B, Fromholt SE, Hess EJ, Crawford TO, Grifﬁn JW, Sheikh KA, Schnaar
RL. 2005. Myelin-associated glycoprotein and complementary axonal
ligands, gangliosides, mediate axon stability in the CNS and PNS: neuro-
pathology and behavioral deﬁcits in single- and double-null mice. Exp
Neurol. 195:208–217.
Park JW, Park WJ, Kuperman Y, Boura-Halfon S, Pewzner-Jung Y, Futerman
AH. 2013. Ablation of very long acyl chain sphingolipids causes hepatic
insulin resistance in mice due to altered detergent-resistant membranes.
Hepatology. 57:525–532.
Rohrer JS. 2000. Analyzing sialic acids using high-performance anion-
exchange chromatography with pulsed amperometric detection. Anal
Biochem. 283:3–9.
Saltiel AR. 2016. Insulin signaling in the control of glucose and lipid homeo-
stasis. Handb Exp Pharmacol. 233:51–71.
Sasaki A, Hata K, Suzuki S, Sawada M, Wada T, Yamaguchi K, Obinata M,
Tateno H, Suzuki H, Miyagi T. 2003. Overexpression of plasma
membrane-associated sialidase attenuates insulin signaling in transgenic
mice. J Biol Chem. 278:27896–27902.
Sasaki N, Itakura Y, Toyoda M. 2015. Ganglioside GM1 contributes to the
state of insulin resistance in senescent human arterial endothelial cells.
J Biol Chem. 290:25475–25486.
Schauer R. 2009. Sialic acids as regulators of molecular and cellular interac-
tions. Curr Opin Struct Biol. 19:507–514.
Schnaar RL. 1994. Isolation of glycosphingolipids. Methods Enzymol. 230:
348–370.
Schnaar RL. 2016. Gangliosides of the vertebrate nervous system. J Mol Biol.
427:3325–3336.
Schnaar RL, Gerardy-Schahn R, Hildebrandt H. 2014. Sialic acids in the
brain: gangliosides and polysialic acid in nervous system development,
stability, disease and regeneration. Physiol Rev. 94:461–518.
Schnaar RL, Needham LK. 1994. Thin-layer chromatography of glycosphin-
golipids. Methods Enzymol. 230:371–389.
Sonnino S, Prinetti A. 2010. Gangliosides as regulators of cell membrane
organization and functions. Adv Exp Med Biol. 688:165–184.
Sturgill ER, Aoki K, Lopez PH, Colacurcio D, Vajn K, Lorenzini I, Majic
S, Yang WH, Heffer M, Tiemeyer M, et al. 2012. Biosynthesis of the
major brain gangliosides GD1a and GT1b. Glycobiology. 22:
1289–1301.
Svennerholm L. 1994. Designation and schematic structure of gangliosides
and allied glycosphingolipids. Prog Brain Res. 101:xi–xiv.
Tagami S, Inokuchi JJ, Kabayama K, Yoshimura H, Kitamura F, Uemura S,
Ogawa C, Ishii A, Saito M, Ohtsuka Y, et al. 2002. Ganglioside GM3
participates in the pathological conditions of insulin resistance. J Biol
Chem. 277:3085–3092.
Tanabe A, Matsuda M, Fukuhara A, Miyata Y, Komuro R, Shimomura I,
Tojo H. 2009. Obesity causes a shift in metabolic ﬂow of gangliosides in
adipose tissues. Biochem Biophys Res Commun. 379:547–552.
Taniguchi N, Honke K, Fukuda M, Narimatsu H, Yamaguchi Y, Angata T.
2014. Handbook of Glycosyltransferases and Related Genes, 2nd ed.
Tokyo, Springer. p. 1707.
Todeschini AR, Hakomori SI. 2008. Functional role of glycosphingolipids
and gangliosides in control of cell adhesion, motility, and growth,
through glycosynaptic microdomains. Biochim Biophys Acta. 1780:
421–433.
Tsuji S, Takashima S. 2014. ST3 beta-galactoside alpha-2,3-sialyltransferase
2 (ST3GAL2). In: Taniguchi N, Honke K, Fukuda M, Narimatsu H,
Yamaguchi Y, Angata T editors. Handbook of Glycosyltransferases and
Related Genes, 2nd ed. Tokyo, Springer. p. 645–656.
van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CP, Dubbelhuis PF,
Seeman I, Ghauharali-van der Vlught Karen, Overkleeft HS, Arbeeny C,
et al. 2009. Reducing glycosphingolipid content in adipose tissue of obese
mice restores insulin sensitivity, adipogenesis and reduces inﬂammation.
PLoS ONE. 4:e4723.
Varki A, Cummings RD, Aebi M, Packer NH, Seeberger PH, Esko JD,
Stanley P, Hart G, Darvill A, Kinoshita T, et al. 2015. Symbol nomencla-
ture for graphical representations of glycans. Glycobiology. 25:
1323–1324.
Veillon L, Go S, Matsuyama W, Suzuki A, Nagasaki M, Yatomi Y, Inokuchi
J. 2015. Identiﬁcation of ganglioside GM3 molecular species in human
serum associated with risk factors of metabolic syndrome. PLoS ONE.
10:e0129645.
Vukelic Z, Zamﬁr AD, Bindila L, Froesch M, Peter-Katalinic J, Usuki S, Yu
RK. 2005. Screening and sequencing of complex sialylated and sulfated
glycosphingolipid mixtures by negative ion electrospray Fourier transform
ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom. 16:
571–580.
Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A,
Kono M, Tsuji S, Daniotti JL, Werth N, et al. 2003. Enhanced insulin
sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci. U S A.
100:3445–3449.
Yew NS, Zhao H, Hong EG, Wu IH, Przybylska M, Siegel C, Shayman JA,
Arbeeny CM, Kim JK, Jiang C, et al. 2010. Increased hepatic insulin
action in diet-induced obese mice following inhibition of glucosylceramide
synthase. PLoS ONE. 5:e11239.
Yoo SW, Motari MG, Susuki K, Prendergast J, Mountney A, Hurtado A,
Schnaar RL. 2015. Sialylation regulates brain structure and function.
FASEB J. 29:3040–3053.
Zakharova IO, Sokolova TV, Vlasova YA, Furaev VV, Rychkova MP,
Avrova NF. 2014. GM1 ganglioside activates ERK1/2 and Akt down-
stream of Trk tyrosine kinase and protects PC12 cells against hydrogen
peroxide toxicity. Neurochem Res. 39:2262–2275.
Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS,
Cheng SH. 2007. Inhibiting glycosphingolipid synthesis improves gly-
cemic control and insulin sensitivity in animal models of type 2 diabetes.
Diabetes. 56:1210–1218.
139St3gal2-null mice develop late-onset obesity
